About > Company
The Adial Vision
To build the world’s leading pharmaceutical company focused on improving the quality of life of patients by preventing and treating addiction and other unmet medical needs.
The Adial Story
Adial was founded on the ground-breaking work of Bankole A. Johnson, M.D., D.Sc. Dr. Johnson began his work in the 1990’s and, once the genome was unlocked, focused on understanding the genetics behind addiction. After animal studies, imaging studies, and early clinical work, he hypothesized that a serotonin-3 blocker might help people with certain genetics related to the serotonin system. After a Phase 2 study conducted by the University of Virginia at three sites in Virginia and one site in Texas, he met William Stilley and Adial Pharmaceuticals was founded in 2010 and began operations in 2011.
Licenses AD04 from the University of Virginia
USPTO grants 1st U.S. patent for AD04 for the treatment of Alcohol Use Disorder (AUD) in genetically targeted patients
Adial Pharmaceuticals listed on U.S. NASDAQ
ONWARD Phase 3
ADO4 Onward Phase 3 Trials begin
ONWARD Phase 3 Trials completed
ONWARD Phase 3 Trial results announced